Vinay Prasad's exit signals FDA's probable slip toward more permissive regulation of cell and gene therapy: analyst

Dr. Vinay Prasad's abrupt departure from the FDA's CBER, less than three months into his role, signals a potential shift towards a more permissive 'right to try' regulatory stance, contrasting with his advocacy for stricter drug approval standards. His exit, occurring shortly after the FDA reversed its stance on Sarepta's Elevidys amid political pressure, suggests that his successor will likely favor patient advocacy over rigorous data, which Leerink Partners views as an incremental positive for rare disease genetic medicine companies in the short term. However, this shift raises long-term concerns about less stringent data standards leading to safety issues and potentially eroding trust in new therapies, underscoring the importance of consistent and adequately high regulatory barriers for the sector's health.

Analysis

The abrupt departure of Dr. Vinay Prasad as director of the FDA's Center for Biologics Evaluation and Research (CBER) after less than three months signals a significant potential shift in U.S. regulatory policy for the cell and gene therapy sector. Dr. Prasad, known for his stringent, data-driven stance and criticism of accelerated approvals based on surrogate endpoints, represented a philosophy of high regulatory scrutiny. His exit, immediately following the FDA's reversal on a shipping halt for Sarepta Therapeutics' (SRPT) Elevidys amid political pressure, suggests that the more permissive, patient-advocacy-focused "right to try" movement is gaining substantial influence over the agency. Leerink Partners analysis posits that a successor is likely to be more aligned with this lenient approach, which could be an incremental positive for companies like Ultragenyx (RARE) and Capricor (CAPR) that have recently faced regulatory setbacks. However, this development carries significant long-term risks. The article highlights that a lower regulatory bar could lead to approvals on less stringent data, increasing the likelihood of adverse safety events, as exemplified by the liver failure deaths linked to Elevidys. Such outcomes could ultimately undermine patient and investor confidence in the sector, which is already in a multi-year bear market. The most damaging element identified is regulatory inconsistency, as frequent policy changes disrupt clinical trial modeling, financing, and strategic planning for biotech firms.

Key Decisions for Investors

• Investors should anticipate heightened volatility and a potential short-term rally in speculative cell and gene therapy stocks on the expectation of a more lenient FDA, but must weigh this against the increased long-term risk of drug safety issues.
• Closely monitor the appointment and stated philosophy of the next CBER director, as this will be the most critical signal for the future regulatory environment and will dictate long-term investment strategy in the biotech sector.
• For positions in Sarepta Therapeutics (SRPT), the focus should be on the FDA's handling of the Elevidys safety profile, as the company remains at the center of this policy struggle and its valuation is highly sensitive to subsequent regulatory actions.
• It is prudent to increase due diligence on the robustness of clinical trial data for companies nearing approval, as a shift towards "right to try" may permit market entry based on weaker evidence, elevating the risk profile of newly commercialized assets.